Short answer
LENZ Therapeutics, Inc. (LENZ) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 2.05 (Costs Associated with Exit or Disposal Activities). Press release announces LENZ’s financial results for the quarter ended September 30, 2026.
LENZ Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces LENZ’s financial results for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed earnings figures and management commentary
- Results release dated October 28, 2026, giving investors the company’s latest quarterly performance update
Item 2.05 · Costs Associated with Exit or Disposal Activities
- Strategic reorganization prioritizes consumer marketing and sales-growth capital allocation
- Headcount reduced approximately 75%, leaving approximately 40 full-time employees
- Estimated non-recurring charges approximately $5 million, primarily severance and termination benefits
- Substantially all charges expected in fourth quarter 2026, with completion targeted during the same quarter
Item 5.02 · Departure/Election of Directors or Officers
- CEO Evert Schimmelpennink departs December 1, 2026, resigning from the Board; transition is stated as non-disputed
- CFO Daniel Chevallard becomes Interim President and CEO while retaining CFO, principal financial and accounting officer responsibilities
- CEO separation benefits total $1,040,416.50 in cash, plus up to 12 months of COBRA premiums
- Chevallard’s interim compensation rises to $650,000 salary and 60% target bonus, plus approximately $1,500,000 equity award
- Retention program grants Chevallard, Marc Odrich and Shawn Olsson bonuses equal to 75% of 2026 target bonuses, split between cash and performance-based stock units
Item EX-99.1 · Exhibit EX-99.1
- Q3 product sales $2.6M, up 50% sequentially, with 38,000 paid prescriptions, supporting accelerating VIZZ adoption
- Telehealth generated over 50% of incremental prescriptions, expanding access beyond traditional eye-care channels
- Reorganization targets 2027 operating expenses of approximately $70M to $75M, excluding stock compensation, down over 50%
- Q4 restructuring expected to incur approximately $5M in one-time net charges, creating near-term earnings pressure
- CEO Eef Schimmelpennink transitions December 1, 2026; CFO Dan Chevallard becomes Interim CEO during commercialization reset
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LENZ Therapeutics, Inc. 8-K filings
Get the next LENZ 8-K as it lands
Follow LENZ for push alerts, or ask the research agent what this filing means.